Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | 2026-03-03 16:53:14 | 40.12 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNX | 0001658247 | Crinetics Pharmaceuticals, Inc. | US22663K1079 | 549300Q1CNFXK5P31D28 | 263744114 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 6055 LUSK BLVD. | SAN DIEGO | CA | 92121 | UNITED STATES | US | 858-450-6464 | 6055 LUSK BLVD., SAN DIEGO, CA, 92121 | 6055 LUSK BLVD., SAN DIEGO, CA, 92121 | — | — | 2008 | — | 437 | https://crinetics.com | 3,500,000,000 | 94,548,000 | 94,891,840 | Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. | 2026-02-26 16:46:13 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 2,700,000,000 | -800,000,000 | -22.8571 | 104,705,330 | 11,656,792 | 12.5276 |
| 2024 | 3,500,000,000 | 2,500,000,000 | 250 | 93,048,538 | 23,452,336 | 33.6977 |
| 2023 | 1,000,000,000 | 0 | 0 | 69,596,202 | 15,687,337 | 29.0997 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Dana Pizzuti | Chief Development Officer | 2024 | 550,833 | 0 | 1,000,730 | 247,875 | 3,000 | 4,209,728 |
| Stephen F. Betz | Chief Scientific Officer | 2024 | 491,667 | 0 | 1,000,730 | 221,250 | 3,000 | 4,123,937 |
| R. Scott Struthers | Chief Executive Officer, President | 2024 | 653,833 | 0 | 2,828,150 | 407,796 | 3,000 | 10,533,579 |
| Marc Wilson | Chief Financial Officer | 2024 | 468,900 | 0 | 1,109,505 | 211,005 | 3,000 | 4,434,895 |
| Jeff Knight | Chief Operating Officer | 2024 | 490,000 | 0 | 1,000,730 | 221,970 | 3,000 | 4,122,990 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 594 |
| 2024 | 437 |
| 2023 | 290 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 7,696,000 | 1,039,000 | 4,013,000 |
| Cost Of Revenue | 1,076,000 | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 332,058,000 | 240,156,000 | 168,527,000 |
| General And Administrative Expenses | 191,331,000 | 99,737,000 | 58,094,000 |
| Operating Expenses | 524,465,000 | 339,893,000 | 226,621,000 |
| Operating Income | -516,769,000 | -338,854,000 | -222,608,000 |
| Net Income | -465,317,000 | -298,408,000 | -214,529,000 |
| Earnings Per Share Basic | -4.95 | -3.69 | -3.69 |
| Earnings Per Share Diluted | -4.95 | -3.69 | -3.69 |
| Weighted Average Shares Outstanding Basic | 94,057,000 | 80,783,000 | 58,071,000 |
| Weighted Average Shares Outstanding Diluted | 94,057,000 | 80,783,000 | 58,071,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 101,536,000 | 264,545,000 | 54,897,000 |
| Marketable Securities Current | 926,353,000 | 232,921,000 | 74,092,000 |
| Accounts Receivable | 592,000 | — | — |
| Inventories | 2,022,000 | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 3,456,000 | 1,207,000 | 1,578,000 |
| Total Assets Current | 1,048,342,000 | 1,375,388,000 | 574,153,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 14,296,000 | 12,068,000 | 10,881,000 |
| Other Assets Non Current | — | 2,829,000 | 2,000,000 |
| Total Assets Non Current | 77,915,000 | 59,204,000 | 61,200,000 |
| Total Assets | 1,126,257,000 | 1,434,592,000 | 635,353,000 |
| Accounts Payable | 22,611,000 | 5,853,000 | 6,548,000 |
| Deferred Revenue | 1,235,000 | 2,176,000 | 2,056,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 85,072,000 | 59,684,000 | 43,942,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 3,240,000 | 829,000 | — |
| Total Liabilities Non Current | 49,102,000 | 50,103,000 | 52,305,000 |
| Total Liabilities | 134,174,000 | 109,787,000 | 96,247,000 |
| Common Stock | 2,407,757,000 | 2,275,952,000 | 253,000 |
| Retained Earnings | -1,417,427,000 | -952,110,000 | -653,702,000 |
| Accumulated Other Comprehensive Income | 1,865,000 | 963,000 | 977,000 |
| Total Shareholders Equity | 992,083,000 | 1,324,805,000 | 539,106,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 3,890,000 | 2,785,000 | 1,098,000 |
| Share Based Compensation Expense | 91,024,000 | 69,386,000 | 40,937,000 |
| Other Non Cash Income Expense | -50,000 | -51,000 | 0 |
| Change In Accounts Receivable | 592,000 | — | — |
| Change In Inventories | 2,022,000 | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 28,983,000 | 17,541,000 | 14,648,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -377,922,000 | -225,970,000 | -166,307,000 |
| Purchases Of Marketable Securities | 1,004,427,000 | 1,146,772,000 | 527,857,000 |
| Sales Of Marketable Securities | 1,184,097,000 | 575,799,000 | 337,132,000 |
| Acquisition Of Property Plant And Equipment | 5,762,000 | 3,844,000 | 4,688,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 173,908,000 | -574,817,000 | -200,413,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 0 | 970,048,000 | 369,019,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 40,611,000 | 1,010,435,000 | 388,944,000 |
| Change In Cash | -163,403,000 | 209,648,000 | 22,224,000 |
| Cash At End Of Period | 101,536,000 | 264,545,000 | 54,897,000 |
| Income Taxes Paid | 89,000 | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -4.95 | -3.69 | -3.69 |
| Price To Earnings Ratio | -9.404 | -13.8564 | -9.6423 |
| Earnings Growth Rate | 34.1463 | 0 | 17.1429 |
| Price Earnings To Growth Ratio | -0.2754 | — | -0.5625 |
| Book Value Per Share | 10.5477 | 16.3996 | 9.2836 |
| Price To Book Ratio | 4.4133 | 3.1178 | 3.8326 |
| Ebitda | -461,338,000 | -295,623,000 | -213,431,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 6,118,000 | 3,972,000 | 8,479,000 |
| Free Cash Flow | -384,040,000 | -229,942,000 | -174,786,000 |
| Return On Equity | -0.469 | -0.2252 | -0.3979 |
| One Year Beta | 1.1526 | 1.2961 | 0.9832 |
| Three Year Beta | 1.1412 | 1.1657 | 1.1631 |
| Five Year Beta | 1.1718 | 1.142 | 1.1278 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Kalofonos Isabel | Chief Commercial Officer | 2026-02-23 | 34,000 | A | 34,834 |
| Kalofonos Isabel | Chief Commercial Officer | 2026-02-23 | 55,000 | A | 55,000 |
| Betz Stephen F. | Chief Scientific Officer | 2026-02-23 | 30,000 | A | 147,713 |
| Betz Stephen F. | Chief Scientific Officer | 2026-02-23 | 47,000 | A | 47,000 |
| Knight Jeff E. | Chief Operating Officer | 2026-02-23 | 34,000 | A | 121,929 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2025-05-06 | CA31 | Purchase | 2025-04-17 | — | $1,001 - $15,000 |
| Josh Gottheimer | 2025-04-10 | NJ05 | Sale | 2025-03-19 | Joint | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-02-11 | CA31 | Purchase | 2025-01-29 | — | $1,001 - $15,000 |
| Josh Gottheimer | 2024-10-03 | NJ05 | Purchase | 2024-09-25 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Bell Investment Advisors, Inc | 2025-12-31 | 792 | 17 | 46.5882 |
| T. Rowe Price Investment Management, Inc. | 2025-12-31 | 2,753,000 | 59,121 | 46.5655 |
| Invesco Ltd. | 2025-12-31 | 7,359,043 | 158,089 | 46.55 |
| ADAR1 Capital Management, LLC | 2025-12-31 | 14,401,080 | 309,368 | 46.55 |
| MACKENZIE FINANCIAL CORP | 2025-12-31 | 267,983 | 5,666 | 47.2967 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCMX | 124 | 5,772.2 | 0.0684 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYAKX | 124 | 5,772.2 | 0.0684 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYMKX | 124 | 5,772.2 | 0.0684 |
| RYDEX DYNAMIC FUNDS | 2025-12-31 | H-Class Shares | RYRSX | 449 | 20,900.95 | 0.0383 |
| RYDEX DYNAMIC FUNDS | 2025-12-31 | C-Class Shares | RYRLX | 449 | 20,900.95 | 0.0383 |